サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1610027

神経痛治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント予測、2025年～2030年

Neuralgia Treatment Market Size, Share & Trends Analysis Report By Treatment (Drug Based, Surgery), By End Use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
神経痛治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月12日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

神経痛治療市場の成長と動向

世界の神経痛治療市場規模は2030年に34億3,000万米ドルに達すると予測され、2025～2030年にかけてCAGR 6.7％で成長すると予測されます。

高齢者の増加、三叉神経痛の発生率の増加、糖尿病の有病率の増加が市場を牽引する主要要因です。神経痛は、神経の損傷や炎症による灼熱感、刺すような激痛です。

神経の慢性的な痛みは、感染症、糖尿病、加齢、多発性硬化症、あるいは特定の神経を保護するミエリン鞘を損傷する同様の疾患など、さまざまな要因によって発生する可能性があります。三叉神経を圧迫する腫瘍もこの疾患の原因となります。三叉神経の慢性疼痛の有病率は高齢化とともに増加します。WHOが発表した推定によると、高齢者は2015年の9億人から2050年には20億人に増加すると予測されています。高齢者は糖尿病や三叉神経痛など多くの病気にかかりやすいです。

米国神経筋・電気診断医療会によると、三叉神経痛は通常50歳以上で発症します。また、三叉神経痛は男性よりも女性の方がなりやすいと報告されています。International Association for The Study of Pain（IASP）が発表したThe Patient's Journey Through Trigeminal Neuralgiaという研究によると、一般人口における三叉神経痛の発症率は人口10万人あたり3.4～5.9人です。また、高齢者における発症率が比較的高いことも報告されています。このような要因が、予測期間中の市場成長を押し上げると予想されます。定位放射線手術と微小血管減圧術は、この疾患の治療に採用されている最も一般的な治療法です。

神経痛治療市場のレポートハイライト

  • 外科手術セグメントが市場を独占し、2024年には64.8%のシェアを占める。ロボットによる放射線手術のような、正確で非侵襲的な治療オプションに対する需要の高まりが、このセグメントの主要な促進要因となっています。
  • 薬剤ベースのセグメントは、予測期間中最も速いCAGR 7.0％で成長する見込みです。
  • 病院・クリニックセグメントは、2024年に最大の市場収益シェアを占めました。病院・クリニックにおける先進的な非侵襲的技術の採用は、より正確で的を絞った治療を提供することで市場を牽引します。
  • 外来手術センターセグメントは予測期間で最も速いCAGRで成長すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 神経痛治療の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 神経痛治療市場：治療別ビジネス分析

  • 治療市場シェア、2024年と2030年
  • 治療セグメントダッシュボード
  • 市場規模と予測と動向分析、治療別、2018～2030年
  • 薬剤ベース
  • 手術

第5章 神経痛治療市場：最終用途別ビジネス分析

  • 最終用途市場シェア、2024年と2030年
  • 最終用途セグメントダッシュボード
  • 市場規模と予測と動向分析、最終用途別、2018～2030年
  • 病院・クリニック
  • 外来手術センター
  • その他

第6章 神経痛治療市場：国別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • GSK plc.
    • Pfizer Inc.
    • Novartis AG
    • Biogen
    • Zydus Group（Cadila Healthcare Limited）
    • H. Lundbeck A/S
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global neuralgia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global neuralgia treatment market, by product, 2018 - 2030 (USD Million)
  • Table 5. Global neuralgia treatment market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global neuralgia treatment market, by portability, 2018 - 2030 (USD Million)
  • Table 7. Global neuralgia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8. Global neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9. North America neuralgia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 10. North America neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11. North America neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 12. U.S. neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13. U.S. Neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Canada neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15. Canada neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16. Mexico neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17. Mexico neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18. Europe neuralgia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 19. Europe neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20. Europe neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 21. UK neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22. UK Neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 23. Germany neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24. Germany neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 25. France neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26. France Neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 27. Italy neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28. Italy neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 29. Spain neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30. Spain neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 31. Russia neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32. Russia neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33. Denmark neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34. Denmark neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35. Sweden neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36. Sweden neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37. Norway neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38. Norway Neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39. Asia Pacific neuralgia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 40. Asia Pacific neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41. Asia Pacific neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Japan neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 43. Japan neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 44. China neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 45. China neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 46. India neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47. India neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Australia neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49. Australia neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50. South Korea neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51. South Korea neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52. Thailand neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53. Thailand neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54. Latin America neuralgia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 55. Latin America neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56. Latin America neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57. Brazil neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58. Brazil neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59. Argentina neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60. Argentina neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61. Middle East & Africa Neuralgia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 62. Middle East & Africa neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63. Middle East & Africa neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 64. South Africa neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65. South Africa neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 66. Saudi Arabia neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 67. Saudi Arabia neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 68. UAE neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 69. UAE neuralgia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Kuwait neuralgia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 71. Kuwait neuralgia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Neuralgia Treatment segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end use outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Neuralgia treatment dynamics
  • Fig. 12 Neuralgia treatment market: Porter's five forces analysis
  • Fig. 13 Neuralgia treatment market: PESTLE analysis
  • Fig. 14 Neuralgia treatment market: Treatment segment dashboard
  • Fig. 15 Neuralgia treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Drug based market, 2018 - 2030 (USD Million)
  • Fig. 17 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 18 Neuralgia treatment market: End Use segment dashboard
  • Fig. 19 Neuralgia treatment market: End Use market share analysis, 2024 & 2030
  • Fig. 20 Radiofrequency thermal lesioning market, 2018 - 2030 (USD Million)
  • Fig. 21 Stereotactic radiosurgery market, 2018 - 2030 (USD Million)
  • Fig. 22 Microvascular decompression market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Neuralgia treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Russia country dynamics
  • Fig. 46 Russia neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait Key country dynamics
  • Fig. 79 Kuwait neuralgia treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
目次
Product Code: GVR-4-68039-022-8

Neuralgia Treatment Market Growth & Trends:

The global neuralgia treatment market size is expected to reach USD 3.43 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030. The rising geriatric population, increasing incidence of trigeminal neuralgia, and the growing prevalence of diabetes are the key factors driving the market. Neuralgia is a burning, stabbing, and severe pain due to a damaged or irritated nerve.

The chronic pain in the nerves can occur due to various factors such as infection, diabetes, aging, multiple sclerosis, or any similar disorders that damage the myelin sheath protecting certain nerves. Tumor compressing the trigeminal nerve can also cause the disorder. The prevalence of chronic pain in the trigeminal nerve increases with the aging population. According to the estimates published by the WHO, the geriatric population is anticipated to rise from 900.0 million in 2015 to 2.0 billion in 2050. The geriatric population is prone to many diseases such as diabetes and trigeminal neuralgia.

As per the American Association of Neuromuscular and Electrodiagnostic Medicine, the disorder usually affects the population aged 50 years or older. It also reported that women are more prone to trigeminal neuralgia than men. As per the study, The Patient's Journey Through Trigeminal Neuralgia published by the International Association for The Study of Pain (IASP), the incidence rate of the disorder in the general population is 3.4 to 5.9 per 100,000 population. It also reported that the incidence rate is comparatively higher in the geriatric population. Such factors are expected to boost market growth over the forecast period. Stereotactic radiosurgery and microvascular decompression are the two most common procedures being adopted to treat the disorder.

Neuralgia Treatment Market Report Highlights:

  • The surgery segment dominated the market and accounted for a share of 64.8% in 2024. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a key driver for the segment
  • The drug-based segment is expected to grow at the fastest CAGR of 7.0% over the forecast period
  • The hospital & clinics segment accounted for the largest market revenue share in 2024. Adopting advanced, non-invasive technologies in hospitals and clinics drives the market by providing more accurate and targeted treatments
  • The ambulatory surgery centers segment is expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Neuralgia Treatment Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Neuralgia Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Drug Based
    • 4.4.1. Drug based market, 2018 - 2030 (USD Million)
    • 4.4.2. Anticonvulsant medicines
      • 4.4.2.1. Anticonvulsant medicines market, 2018 - 2030 (USD Million)
    • 4.4.3. Tricyclic antidepressants
      • 4.4.3.1. Tricyclic antidepressants market, 2018 - 2030 (USD Million)
  • 4.5. Surgery
    • 4.5.1. Surgery market, 2018 - 2030 (USD Million)
    • 4.5.2. Radiofrequency Thermal Lesioning
      • 4.5.2.1. Radiofrequency thermal lesioning market, 2018 - 2030 (USD Million)
    • 4.5.3. Stereotactic Radiosurgery
      • 4.5.3.1. Stereotactic radiosurgery market, 2018 - 2030 (USD Million)
    • 4.5.4. Microvascular Decompression
      • 4.5.4.1. Microvascular decompression market, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Neuralgia Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospital & Clinics
    • 5.4.1. Hospital & clinics market, 2018 - 2030 (USD Million)
  • 5.5. Ambulatory Surgery Centers
    • 5.5.1. Ambulatory surgery centers market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Neuralgia Treatment Market: Country Estimates & Trend Analysis by Product and Technology

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamic
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. U.S. neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamic
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. Canada neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamic
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. Mexico neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamic
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. UK neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key country dynamic
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. Germany neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamic
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. France neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamic
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. Italy neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamic
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Spain neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Russia
      • 6.5.7.1. Key country dynamic
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive insights
      • 6.5.7.4. Russia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamic
      • 6.5.8.2. Regulatory framework
      • 6.5.8.3. Competitive insights
      • 6.5.8.4. Denmark neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key country dynamic
      • 6.5.9.2. Regulatory framework
      • 6.5.9.3. Competitive insights
      • 6.5.9.4. Sweden neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.10. Norway
      • 6.5.10.1. Key country dynamic
      • 6.5.10.2. Regulatory framework
      • 6.5.10.3. Competitive insights
      • 6.5.10.4. Norway neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key country dynamic
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. Japan neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key country dynamic
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. China neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamic
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive insights
      • 6.6.4.4. India neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamic
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive insights
      • 6.6.5.4. Australia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamic
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive insights
      • 6.6.6.4. Thailand neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. South Korea
      • 6.6.7.1. Key country dynamic
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive insights
      • 6.6.7.4. South Korea neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamic
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. Brazil neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamic
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Argentina neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key country dynamic
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive insights
      • 6.8.2.4. South Africa neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key country dynamic
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive insights
      • 6.8.3.4. Saudi Arabia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key country dynamic
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive insights
      • 6.8.4.4. UAE neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key country dynamic
      • 6.8.5.2. Regulatory framework
      • 6.8.5.3. Competitive insights
      • 6.8.5.4. Kuwait neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. GSK plc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Pfizer Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. Biogen
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. Zydus Group (Cadila Healthcare Limited)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. H. Lundbeck A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives